# Lenz Therapeutics Inc (LENZ) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LENZ
## Company Profile
- Ticker: LENZ
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: 5.27 USD
- Market cap: 223556829.22 USD
- Last updated: 2026-08-05
## Business Overview
### Presbyopia-Focused Company
LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision.
### VIZZ
VIZZ is an aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation. It is the company's principal commercial product and the foundation of its presbyopia franchise. LENZ markets VIZZ through eye-care professionals while also building consumer awareness through direct-to-consumer outreach. Its strategy depends on prescription generation, patient trial and repeat use in a newly developing treatment category.
## Why The Stock Is Moving

Following the latest company update, “LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026”, LENZ closed up 4.36% at $5.27 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- LENZ’s catalysts are cataract / ophthalmology platform updates and any commercialization or clinical step that clarifies the company’s path. The market will care about whether the eye-care story keeps building.

## Recent News
- 2026-08-04 20:05 EST — [LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-report-second-quarter-2026-financial-results-and-recent-cor-62eb13db) — Source: Lenz Therapeutics Inc
- 2026-07-06 12:15 EST — [LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-launch-of-new-telehealth-prescribing-option-to-accel-e7f681dd) — Source: Lenz Therapeutics Inc
- 2026-06-24 12:30 EST — [LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-license-and-com-069a15c4) — Source: Lenz Therapeutics Inc
- 2026-06-07 23:30 EST — [LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-com-434c4009) — Source: Lenz Therapeutics Inc
- 2026-05-26 12:00 EST — [LENZ Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/LENZ/lenz-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Lenz Therapeutics Inc